Advances in biofunctional SERS-active nanoparticles for future clinical diagnostics and therapeutics

Steven Asiala, Lee Barrett, Samuel Mabbott, Duncan Graham

Research output: Chapter in Book/Report/Conference proceedingChapter


The synergy afforded by the combination of biofunctionalised nanoparticles and surface enhanced Raman scattering (SERS) has expanded the analytical toolbox for clinical diagnostics and therapeutics. Since their inception, SERS-active nanoparticles have been developed into biofunctional nanoparticles (BFNPs) using a variety of methods to attach biomolecules and pacification layers to nanoparticles to enable detection of various diseases or cancers in vitro and in vivo. However, while there are many reports of the use of BFNPs for diagnostic or therapeutic applications, very few are implemented in a “real” clinical setting, for example, detection of disease biomarkers in tissue or the delivery of drugs to affected cells. This review covers recent advances made in the development of BFNPs for SERS-based detection of clinical samples using in vitro and in vivo methods.
Original languageEnglish
Title of host publicationFrontiers of Plasmon Enhanced Spectroscopy
EditorsYukihiro Ozaki, George C. Schatz, Duncan Graham, Tamitake Itoh
Place of PublicationWashington, DC
PublisherAmerican Chemical Society
Number of pages31
ISBN (Print)9780841232013
Publication statusPublished - 20 Dec 2016

Publication series

NameACS Symposium Series
PublisherAmerican Chemical Society


  • nanoparticles
  • biofunctionalised
  • synergy
  • surface enhanced Raman scattering
  • biofunctional nanoparticles
  • SERS-based detection
  • in-vitro
  • in-vivo
  • clinical diagnostics
  • therapeutics

Fingerprint Dive into the research topics of 'Advances in biofunctional SERS-active nanoparticles for future clinical diagnostics and therapeutics'. Together they form a unique fingerprint.

Cite this